scispace - formally typeset
B

Bo Lu

Researcher at Ohio State University

Publications -  390
Citations -  24905

Bo Lu is an academic researcher from Ohio State University. The author has contributed to research in topics: Cancer & Lung cancer. The author has an hindex of 58, co-authored 353 publications receiving 21823 citations. Previous affiliations of Bo Lu include Wuhan University of Technology & Wuhan University.

Papers
More filters
Journal ArticleDOI

Genome-wide CRISPR screening reveals genetic modifiers of mutant EGFR dependence in human NSCLC.

TL;DR: A genome-wide CRISPR-Cas9 screening uncovered a spectrum of previously unidentified regulators of EGFR TKI sensitivity in EGFR-mutant human NSCLC, providing insights into the heterogeneity of EGfr TKI treatment responses.
Journal ArticleDOI

Decreased Survival After Combining Thoracic Irradiation and an Anti-PD-1 Antibody Correlated With Increased T-cell Infiltration Into Cardiac and Lung Tissues.

TL;DR: Combining anti-PD-1 treatment and thoracic radiation has potential for improving the outcomes of locally advanced lung cancer over traditional chemoradiation regimens, but the effect of combining these therapies on non-malignant lung tissue has not yet been investigated in preclinical models.
Journal ArticleDOI

Galactosyl conjugated N-succinyl-chitosan-graft-polyethylenimine for targeting gene transfer

TL;DR: NSC-g-PEI-LA has the potential to be used as a safe and effective targeting gene vector with hepatocyte targeting properties and has a lower cytotoxicity than PEI and the toxicity decreased with increasing substitution of LA.
Journal ArticleDOI

ALDH7A1 expression is associated with recurrence in patients with surgically resected non-small-cell lung carcinoma

TL;DR: For patients with NSCLC, low ALDH7A1 expression was associated with a decreased incidence of cancer recurrence and improved recurrence-free and overall survival, suggesting a predictive role in surgically treated patients.
Journal Article

Receptor tyrosine kinase inhibitors as anti-angiogenic agents.

TL;DR: Preclinical and clinical data from representative anti-angiogenic RTK inhibitors will be discussed in this review.